Dashboard PDUFA PDUFA History Dilution Watch Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Track NUVL with free AI briefings, catalyst countdowns, and dilution alerts.

NUVL · Nuvalent, Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$1.3B Cash on Hand

46.6mo Cash Runway

6.2% Short Interest

$124 Analyst Target (9)

Follow NUVL by email Get an email when NUVL pushes back a promised milestone, files for a stock offering or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about NUVL, unsubscribe in one click. Privacy

🧪 Trial & FDA Catalysts

Jan 2027 · Phase 1 · Recruiting · A Study of NVL-330 in Patients With Advanced or Metastatic HER2-altered NSCLC (HEROEX-1)
Registry primary completion date, not a results date
Dec 2027 · Phase 1/2 · Recruiting · A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Har
Registry primary completion date, not a results date
Dec 2027 · Phase 1/2 · Recruiting · A Study of Zidesamtinib (NVL-520) in Patients With Advanced NSCLC and Other Solid Tumors H
Registry primary completion date, not a results date
Dec 2029 · Phase 3 · Recruiting · Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC
Registry primary completion date, not a results date

📊 Drug Pipeline

Drug	Indication	Most advanced trial	Status
Zidesamtinib (NVL-520) FDA approved Jul 2026 · Jideytro	Locally Advanced Solid Tumor	Phase 1/2 · NCT05118789	Recruiting
Alectinib	Non-small Cell Lung Cancer	Phase 3 · NCT06765109	Recruiting
ALK Inhibitor NVL-655	Non-small Cell Lung Cancer	Phase 3 · NCT06765109	Recruiting
HER2 Mutant-selective Inhibitor NVL-330	Locally Advanced Solid Tumor	Phase 1 · NCT06521554	Recruiting

Also used in these trials (approved or third-party drugs, not NUVL's own candidates): Itraconazole, Midazolam Hydrochloride, Repaglinide.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

NUVL holds $1.3B in cash and short-term investments (as of Mar 31, 2026) and burns about $82.9M/quarter from operations, an estimated runway of 46.6 months at that rate (BioRadar estimate, not company guidance).

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when NUVL files for a raise →

📈 Recent Insider Activity (Form 4)

Trade date	Insider	Transaction	Shares	Price	Owned after
2026-07-15 filed 2026-07-15	Noci Darlene	Returned to issuer (D)	14,350	–	0
2026-07-15 filed 2026-07-15	Turner Christopher Durant	Other (U)	31,530	$124.00	0
2026-07-15 filed 2026-07-15	Noci Darlene	Returned to issuer (D)	17,500	–	–
2026-07-15 filed 2026-07-15	Noci Darlene	Returned to issuer (D)	37,500	–	–
2026-07-15 filed 2026-07-15	Noci Darlene	Returned to issuer (D)	33,646	–	–

Only open-market purchases (P) and sales (S) are trading decisions. Awards (A), option exercises (M) and tax withholding (F) are compensation mechanics. Source: SEC Form 4.

📅 Past FDA Decisions & Stock Reactions

Date	Drug	Type	Run-up 30d	Decision 1d	After 5d
2026-07-22	zidesamtinib (Jideytro)	NDA	—	—	—

Browse all historical PDUFA outcomes →

Get the full NUVL picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for NUVL and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z